AbbVie faced setbacks with emraclidine's dual pivotal trial failures in schizophrenia treatment, impacting their $8.7B ...

Illumina has moved to dismiss a securities lawsuit against the company’s board members over their $8 billion Grail deal, ...

Eyenovia halted Phase 3 trial of atropine-based myopia treatment after data showed it wouldn't meet primary endpoint. CEO ...

EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...

Trump's HHS nominee Robert F. Kennedy Jr., an anti-vaccine advocate calling for stricter pharma oversight, contrasts with ...

Boston Pharmaceuticals succeeded on the two key endpoints for its Phase 2 MASH study, putting the company in contention with ...